January 8, 2026
PHILADELPHIA, PA & COPENHAGEN, Denmark – Alveus Therapeutics Inc. (“Alveus”), a clinical-stage biotechnology company developing next-generation therapies for obesity and metabolic diseases, today announced its launch with a $159.8 million Series A financing. Proceeds from the financing will support Phase 2 clinical development of ALV-100, the company’s lead program, and Investigational New Drug (IND) filings of several early proprietary development candidates, including its highly selective Amylin peptide agonist.
The Series A was led by New Rhein Healthcare Investors, Andera Partners, and Omega Funds, with participation from Sanofi Capital, Kurma Partners, Avego BioScience Capital, and other healthcare investors. In conjunction with the financing, Jan Van den Bossche, Partner of Andera Partners and Claudio Nessi, Managing Director of Omega Funds, will join the Alveus Board of Directors.